BUZZ-Cyclerion Therapeutics jumps on MIT deal to develop depression drug

Reuters09-24

BUZZ-Cyclerion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> jumps on MIT deal to develop depression drug

** Shares of drug developer Cyclerion Therapeutics CYCN.O rise 43% to $4.33 premarket

** Co said late on Tuesday it is relaunching as a neuropsychiatric-focused firm after signing a licensing deal with the Massachusetts Institute of Technology

** Its lead program targets treatment-resistant depression using anesthetic-based tech

** A mid-stage trial is expected to begin in 2026 with data in 2027, co said

** As of last close, stock down 6.2% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2569477028?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 18:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569477028","market":"fut","top_or_hot":-1,"title":"BUZZ-Cyclerion Therapeutics jumps on MIT deal to develop depression drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Cyclerion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> jumps on MIT deal to develop depression drug</title></head><body><p>** Shares of drug developer Cyclerion Therapeutics <span>CYCN.O</span> rise 43% to $4.33 premarket</p><p>** Co said late on Tuesday it is relaunching as a neuropsychiatric-focused firm after signing a licensing deal with the Massachusetts Institute of Technology</p><p>** Its lead program targets treatment-resistant depression using anesthetic-based tech</p><p>** A mid-stage trial is expected to begin in 2026 with data in 2027, co said</p><p>** As of last close, stock down 6.2% YTD</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Cyclerion Therapeutics jumps on MIT deal to develop depression drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Cyclerion Therapeutics jumps on MIT deal to develop depression drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-24 18:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Cyclerion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> jumps on MIT deal to develop depression drug</title></head><body><p>** Shares of drug developer Cyclerion Therapeutics <span>CYCN.O</span> rise 43% to $4.33 premarket</p><p>** Co said late on Tuesday it is relaunching as a neuropsychiatric-focused firm after signing a licensing deal with the Massachusetts Institute of Technology</p><p>** Its lead program targets treatment-resistant depression using anesthetic-based tech</p><p>** A mid-stage trial is expected to begin in 2026 with data in 2027, co said</p><p>** As of last close, stock down 6.2% YTD</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYCN","symbol_name":"Cyclerion Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nL3N3VB0LT:1","article_id":"2569477028","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569477028","pubTimestamp":1758709618,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Cyclerion Therapeutics jumps on MIT deal to develop depression drug** Shares of drug developer Cyclerion Therapeutics CYCN.O rise 43% to $4.33 premarket** Co said late on Tuesday it is relaunching as a neuropsychiatric-focused firm after signing a licensing deal with the Massachusetts Institute of Technology** Its lead program targets treatment-resistant depression using anesthetic-based tech** A mid-stage trial is expected to begin in 2026 with data in 2027, co said** As of last close, stock down 6.2% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CYCN":"Cyclerion Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BUZZ-Cyclerion Therapeutics与麻省理工学院达成开发抑郁症药物的协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYCN":0.9},"content_text":"BUZZ-Cyclerion Therapeutics jumps on MIT deal to develop depression drug** Shares of drug developer Cyclerion Therapeutics CYCN.O rise 43% to $4.33 premarket** Co said late on Tuesday it is relaunching as a neuropsychiatric-focused firm after signing a licensing deal with the Massachusetts Institute of Technology** Its lead program targets treatment-resistant depression using anesthetic-based tech** A mid-stage trial is expected to begin in 2026 with data in 2027, co said** As of last close, stock down 6.2% YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2569477028","isCrawlerRequest":true}